Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease

Archives of Neurology

Volumn 60, Issue 8, 2003, Pages 1143-1148

  Mufson, Elliott J ^a,d   Ikonomovic, Milos D ^b   Styren, Scot D ^c   Counts, Scott E ^a   Wuu, Joanne ^a   Leurgans, Sue ^a   Bennett, David A ^a   Cochran, Elizabeth J ^a   DeKosky, Steven T ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c SANOFI   (France)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN PROTEIN; CHOLINE ACETYLTRANSFERASE; NERVE GROWTH FACTOR;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; BRAIN LEVEL; BRAIN REGION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

AGED; ALZHEIMER DISEASE; BRAIN; CELL COUNT; CHOLINE O-ACETYLTRANSFERASE; COGNITION DISORDERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NERVE GROWTH FACTOR; NEURONAL PLASTICITY; NEURONS; NEUROPSYCHOLOGICAL TESTS;

EID: 0043025510     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.60.8.1143     Document Type: Article

References (34)

1. Hefti F, Mash DC. Localization of nerve growth factor receptors in the normal human brain and in Alzheimer's disease. Neurobiol Aging. 1989;10:75-87.
2. Tuszynski MH, Amaral DG, Gage FH. Nerve growth factor infusion in the primate brain reduces lesion-induced cholinergic neuronal degeneration. J Neurosci. 1990;10:3604-3614.
3. Smith DE, Roberts J, Gage FH, Tuszynski MH. Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. Proc Natl Acad Sci U S A. 1999;96:10893-10898.
4. Allen SJ, MacGowan SH, Treanor JJS, Feeney R, Wilcock GK, Dawbarn D. Normal B-NGF content in Alzheimer's disease cerebral cortex and hippocampus. Neurosci Lett. 1991;131:135-139.
5. Goedert M, Fine A, Dawbarn D, Wilcock GK, Chao MV. Nerve growth factor receptor mRNA distribution in human brain: normal levels in basal forebrain in Alzheimer's disease. Brain Res Mol Brain Res. 1989;5:1-7.
6. Jette N, Cole MS, Fahnestock M. NGF mRNA is not decreased in frontal cortex from Alzheimer's disease patients. Brain Res Mol Brain Res. 1994;25:242-250.
7. Murase K, Nabeshima T, Robitaille Y, Quirion R, Ogawa M, Hayashi K. NGF level is not decreased in the serum, brain-spinal fluid, hippocampus, or parietal cortex of individuals with Alzheimer's disease. Biochem Biophys Res Commun. 1993;193:198-203.
8. Hellweg R, Gericke CA, Jendroska K, Hartung HD, Cervos-Navarro J. NGF content in the cerebral cortex of non-demented patients with amyloid-plaques and in symptomatic Alzheimer's disease. Int J Dev Neurosci. 1998;16:787-794.
9. Fahnestock M, Scott SA, Jette N, Weingartner JA, Crutcher KA. Nerve growth factor mRNA and protein levels measured in the same tissue from normal and Alzheimer's disease parietal cortex. Brain Res Mol Brain Res. 1996;42:175-178.
10. Crutcher KA, Scott SA, Liang S, Everson WV, Weingartner J. Detection of NGF-like activity in human brain tissue: increased levels in Alzheimer's disease. J Neurosci. 1993;13:2540-2550.
11. Scott SA, Mufson EJ, Weingartner JA, Skau KA, Crutcher KA. Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci. 1995;15:6213-6221.
12. Narisawa-Saito M, Wakabayashi K, Tsuji S, Takahashi H, Nawa H. Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease. Neuroreport. 1996;7:2925-2928.
13. Hock C, Heese K, Muller-Spahn F, et al. Increased CSF levels of nerve growth factor in patients with Alzheimer's disease. Neurology. 2000;54:2009-2011.
14. Tuszynski MH. Gene therapy for neurodegenerative disorders. Lancet. 2002;1:51-57.
15. DeKosky ST, Ikonomovic MD, Styren S, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002;51:145-155.
16. Ikonomovic MD, Mufson EJ, Woo J, Cochran EJ, Bennett DA, DeKosky ST. Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology. J Alzheimers Dis. 2003;5:39-48.
17. Gilmor ML, Erickson JD, Varoqui H, et al. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol. 1999;411:693-704.
18. Mufson EJ, Ma SJ, Cochran EJ, et al. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol. 2000;427:19-30.
19. Kordower JH, Chu Y, Stebbins GT, et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol. 2001;49:202-213.
20. Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59:198-205.
21. Mufson EJ, Ma SY, Dills J, et al. Loss of basal forebrain P75(NTR) immunore-activity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol. 2002;443:136-153.
22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
24. Braak H, Braak E. Neuropathological staging of Alzheimer's disease. Acta Neuropathol. 1991;82:239-259.
25. National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of AD. Neurobiol Aging. 1997;18: S1-S2.
26. Mufson EJ, Chen EY, Cochran EJ, Beckett LA, Bennett DA, Kordower JH. Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment. Exp Neurol. 1999;158:469-490.
27. Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's disease (CERAD), II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479-486.
28. Soderstrom S, Hallbook F, Ibanez CF, Persson H, Ebendal T. Recombinant human beta-nerve growth factor (NGF): biological activity and properties in an enzyme immunoassay. J Neurosci Res. 1990;27:665-677.
29. Lorigados L, Soderstrom S, Ebendal T. Two-site enzyme immunoassay for beta NGF applied to human patient sera. J Neurosci Res. 1992;32:329-339.
30. Poirier J, Delisle M-C, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc Natl Acad Sci U S A. 1995;92:12260-12264.
31. Gomez-Isla T, Price JL, McKeel DWJ, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci. 1996;16:4491-4500.
32. Geddes JW, Monaghan DT, Cotman CW, Lott IT, Kim RC, Chui HC. Plasticity of hippocampal circuitry in Alzheimer's disease. Science. 1985;230:1179-1181.
33. Cotman CW, Matthews DA, Taylor D, Lynch G. Synaptic rearrangement in the dentate gyrus: histochemical evidence of adjustments after lesions in immature and adult rats. Proc Natl Acad Sci U S A. 1973;70:3473-3477.
34. Mufson EJ, Conner JM, Kordower JH. Nerve growth factor in Alzheimer's disease: defective retrograde transport to nucleus basalis. Neuroreport. 1995;6:1063-1066.